Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2005; 26(04): 28-41
DOI: 10.1055/s-0041-1733133
Review Article

Alternative Strategies in the Management of De-Differentiated Thyroid Cancer

CS BAL
Department of Nuclear Medicine,All India Institute of Medical Sciences,New Delhi,India-110029, India
,
AJAY KUMAR
Department of Nuclear Medicine,All India Institute of Medical Sciences,New Delhi,India-110029, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
28 March 2022

© 2005. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Gaoretzki PE, Simon D, Frilling A, et al. Surgical reintervention for differentiated thyroid carcinoma. Brit J. Surgery 1994;80:1131-1134.
  • 2 Schlumberger MJ. Papillary and follicular thyroid carcinoma. NEJM 1998;338:297-306.
  • 3 Ain KB. Anaplastic thyroid carcinoma: behavioul, biology, and therapeutic approaches. Thyroid 1998;8:715-726.
  • 4 Friedman T Overcoming the obstacles to gene therapy. Scientific American 1997;.276:96-101.
  • 5 FeIgner PL. Nonviral strategies for gene therapy, Scientific American 1997;276:102-106.
  • 6 Kosugi S, Sato Y, Matsuda A, et al. High prevalence of T354P sodium/iodide symporter gene mutation in Japanese patients with iodide transport defect who have heterogeneous clinical pictures. J Clin Endocrinol Metab 1998;83:4123-4129.
  • 7 Ringel MD, Anderson J, Souza SL, et al. Expression of the sodium iodide symporter and thyroglobulin genes are reduced in papillary thyroid cancer: Mod Pathol.2001;14:289-296.
  • 8 Lin JD, Chan EC, Chao TC, et al. Expression of sodium iodide symporter in metastatic and follicular human thyroid tissues. Ann Oncol 2000;11:625-629.
  • 9 Venkataraman GM, Yatin M, Marcinek R, Ain KB. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I symporter gene methylation status. J Clin Endocrinol Metab 1999;84:2449-2257.
  • 10 Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N. Predominant intracellular overexpression of the Na/ I symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 2001;86:2697- 2700.
  • 11 Riedel C, Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Bioi Chem. 2001;276:21458-21463.
  • 12 Shimura H, Haraguchi K, Miyazaki A, Endo T & Onaya T, Iodide uptake and experimental I131 therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I-symporter gene. Endocrinology 1997;138:4493-4496.
  • 13 Battista S, Martelli ML, Fedele M, et al. A mutated p53 gene alters thyroid cell differentiation. Oncogene 1995;11:2029-2037.
  • 14 Moretti F, Farsetti A, Soddu S, et al. p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene 1997;14:729-740.
  • 15 Narimatsu M, Nagayama Y, Akino K, et al. Therapeutic usefulness of wild-type p53 gene introduction in a p53-null anaplastic thyroid carcinoma cell line. J Clin Endocrinol Metab 1998;83:3668-3672.
  • 16 Blagosklonny MV, Giannakokou P, Wojtowiez M, et al. Effects of p53-experessing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 1998;83:2516-2522.
  • 17 Yazawa K, Fisher WE, Brunicardi FC, Current progress in suicide gene therapy for cancer. World J Surg 2002;26:783-789.
  • 18 Braiden V, Nagayama Y, Iitaka M, Namba H, Niwa M & Yamashita S. Retrovirus-mediated sucide gene/ prodrug theray targeting thyroid carcinoma using a thyroid-specific promoter. Endocrinology 1998;139:3996-3999.
  • 19 Nishihara E, Nagayama Y, Narimatsu M, et al. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Res 1998;18:1521-525.
  • 20 Zhang R, Minemura K & DeGroot L.J, Immunotherapy for medullary thyroid carcinoma by a replication. defective adenovirus transducing murine Interleukin- 2. Endocrinology 1998;139:601-608.
  • 21 Zhang R. Baunoch D & DeGroot LJ. Genetic immunotherapy for medullary thyroid carcinoma: destruction of tumours in mice by in vivo delivery of adenoviral vector transducing the murine interleukin-2 gene. Thyroid 1998;8:1137-1145.
  • 22 Schott M, Seissler J, Lettmann M, Fouxon V, Scherbaum WA, Feldkamp J, Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination. JCEM 2001;86:4965-4969.
  • 23 Haupt K, Siegel F, Lu M, et al. Induction of a cellular and humoral immune response against the tumour associated antigen calcitonin by genetic immunization. Jn Endocrin. Invest. 1999;22(Suppl):4 (abstract).
  • 24 Weinberg RA. How cancer arises. Scientific American 1996;271:62-75.
  • 25 Love JM, Gudas LJ, Vitamin A, differentiation, and cancer. Curr Opin Cell Biol 1994;6:825-831.
  • 26 Dragnev HD, Rigas RR, Dmitrovsky E. The retinoids and cancer prevention. Oncologist 2000;5:361-368.
  • 27 Schumtzler C, Brtko J, Winzer R, et al. Functional retinoid and thyroid hormone receptors in human thyroid cell lines and tissues. Int J Cancer 1998;76:368- 376.
  • 28 Jakobs TC, Schmutzler C, Meissner J, Kohrle J. The promoter of the human type I 5-deiodinase gene: mapping of the transcription start site and identification of a DR+4 thyroid hormone responsive clement. E J Biochem 1997;247:288-297.
  • 29 Schreck R, Schnieders F, Schmutzler C, Kohrle J. Retinoids stimulate type 1 iodothyronine 5-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-798.
  • 30 Schmutzler C, Winzer R, Mejssner-Wejgl J, Kohrle J. Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancercell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 1997;240:832-838.
  • 31 GeUnwald E, Pakos E, Bender H, et al. Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med 1998;39:1555-1558.
  • 32 Simon D, Kohrle J, REiners C, et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998;22:569-574.
  • 33 Simon D, Korber C, Krausch M, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer final results of a pilot study. Eur J Nucl Med Mol Imaging 2002;29:775-82.
  • 34 Mizukami Y, Nonomura A, Hashimoto T, Kawahara E, Matsukawa S, Matsubara F. Immunohistochemical demonstration of ras p21 oncogene product in normal, benign, and malignant human thyroid tissues. Cancer 1988;61:673-880.
  • 35 Gibbs JB, Pompliano DL, Mosser SD, et al. Selectjve inbibition of farnesyl-protein transferase blocks ras processing in vivo. J BioI Chem 1993;268:7617-7620.
  • 36 Geiger T, Muller M, Monia BP, Fabbro D. Antitumour activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumours transplanted subcutaneously into nude mice. Clin Cancer Res 1997;3:117.9-1185.
  • 37 Huang SM, Lee JC, Wu T.J, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg 2002;25:302-306.
  • 38 Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery 2001;129:552-558.
  • 39 Ohta Y, Endo Y, Tanaka M, et al. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer. Clin Cancer Res 1996;2:1411-1416.
  • 40 Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic impact of EGF-receptor in papillary thyroid carcinoma. Er J Cancer 1993;68:808-812.
  • 41 Haugen DR, Akslen LA, Varhaug JE, Litlehaug JR. Expression of c-erbB-2 protein in papillary thyroid carcinomas. Br J Cancer 1992;65:832-837.
  • 42 Holting T. Siperstein AE, Clark OH, Duh QY. Epidermal growth factor (EGF) and transforming growth factor alpha-stimulated invasion and growth of follicular thyroid cancer cells can be blocked by antagonism to the EGF receptor and tyrosine kinase in vitro. Eur J Endocrinol 1995;132:229-235.
  • 43 Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti- EGF-receptor antibody, Anticancer Res 1997;17:3157- 3159.
  • 44 Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slaman D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 1994;9:1829- 1938.
  • 45 Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularization, and growth of multiple tumour types. Cancer Res 1999;59:99-106.
  • 46 Wedge SR, Ogilvie DJ; Dukes M; et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumour growth following oral administration. Cancer Res 2002;62:4645-4655.
  • 47 Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284-7290.
  • 48 D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-4085.
  • 49 Dziba J, Marcinek G, Venkataraman G, Robinson J; Ain K. Combretastatin A4 phosphate has primary antineoplastic activity against human/thyroid carcinoma cell lines and xenograft tumours. 74th Annual Meeting of the American Thyroid Association, Los Angeles, CA, 2002;p199.
  • 50 Wang S, Lloyd RV, Hutzler M.J. Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin Dl, in the progression of thyroid cancer. Mod Pathol 2000;13:882-887.
  • 51 Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J. Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumours. Mod Pathol 1998;11:169-174.
  • 52 Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res 2001;61:6105-6111.
  • 53 Bretz JD, Rymaszewski M, Arscott PL, et al. TRAIL death pathway expression and induction in thyroid follicular cells. J Biol Chem 1999;274: 23627-23632.
  • 54 Ahmad M, Shi Y. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Oncogene 2000;19:3363-3371.
  • 55 Specht MC, Tucker ON, Hocever M, Gonzalez D, Teng L, Fahey III TJ. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 2002;87:358- 363.
  • 56 Milena Braga-Basaria and Ringel MD. Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer: J Clin Endocrinol Metab 2003;88:1947-1960.
  • 57 Zarnegar R, Brunaud L, Kanauchi H. et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer usiug Trichostatin A, a histone deacetylase inhibitor: Surgery 2002;132:984-990.